Since a HER2-targeting nanobody has entered into clinical trials (NCT04467515) and HER2(Nb)/CD3(scFv) BiTE has shown promising preclinical results, it seems that the nanobody-based anti-HER2 BiTEs have a greater chance to progress to clinical trials for treating HER2+ breast cancers. Here, ERBB2 is linked to breast cancer.